US Discusses Patent Waiver on COVID Vaccines With WHO Chief - Trade Office Sat 15th May 2021 | 12:10 AM
WASHINGTON (UrduPoint News / Sputnik - 15th May, 2021) United States Trade Representative (USTR) Katherine Tai has discussed a patent waiver on COVID-19 vaccines in a virtual meeting with World Health Organization (WHO) Director General Dr. Tedros Adhanom Ghebreyesus, the USTR said on Friday. .Tai today met virtually with . Director General of the WHO to discuss increasing vaccine production, and the proposed waiver to certain provisions of the World Trade Organization s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for the COVID-19 pandemic, the USTR said in a readout.
Piyush Goyal, US Trade Representative discuss COVID-19 vaccine production, TRIPS waiver
During a meeting with Commerce and Industry Minister Piyush Goyal, United States Trade Representative (USTR), Katherine Tai, reaffirmed the commitment of the US to help India
PTI | May 15, 2021 | Updated 08:57 IST
Union Commerce and Industry Minister Piyush Goyal
Union Commerce and Industry Minister Piyush Goyal discussed the proposed waiver to provisions of the World Trade Organization s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for COVID-19-specific items and raising vaccine production with United States Trade Representative (USTR), Katherine Tai, in a virtually meeting on Friday.
During the meeting, Tai conveyed her deep sympathy for the people of India as the country battles a deadly wave of COVID-19 and reaffirmed the commitment of the United States to help India, the USTR said in a readout of the call. India is in the midst of a deadly wave of th
Amid growing calls for vaccine equity, South Africa and India have proposed the suspension of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for the duration of the COVID-19 pandemic. The rationale behind the proposal is that if patent rights were waived, this would result in increased supply and expedited roll-out of vaccines. However, the counterargument is that South Africa can use the mechanisms that already exist in the TRIPS agreement.